United Therapeutics Corporation $UTHR Shares Acquired by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. lifted its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 10.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 18,510 shares of the biotechnology company’s stock after buying an additional 1,806 shares during the period. Oppenheimer Asset Management Inc.’s holdings in United Therapeutics were worth $7,760,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of UTHR. Geneos Wealth Management Inc. grew its holdings in United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares during the period. Vontobel Holding Ltd. raised its holdings in shares of United Therapeutics by 12.0% in the 2nd quarter. Vontobel Holding Ltd. now owns 1,487 shares of the biotechnology company’s stock valued at $427,000 after purchasing an additional 159 shares in the last quarter. US Bancorp DE increased its holdings in shares of United Therapeutics by 16.6% in the second quarter. US Bancorp DE now owns 2,299 shares of the biotechnology company’s stock valued at $661,000 after purchasing an additional 328 shares during the period. Blair William & Co. IL boosted its holdings in United Therapeutics by 22.1% during the second quarter. Blair William & Co. IL now owns 1,343 shares of the biotechnology company’s stock worth $386,000 after buying an additional 243 shares in the last quarter. Finally, IFP Advisors Inc grew its holdings in shares of United Therapeutics by 24.4% in the 2nd quarter. IFP Advisors Inc now owns 2,164 shares of the biotechnology company’s stock worth $622,000 after acquiring an additional 425 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Trading Up 0.0%

UTHR stock opened at $473.20 on Wednesday. The company has a market cap of $20.38 billion, a PE ratio of 17.93, a price-to-earnings-growth ratio of 2.52 and a beta of 0.85. The stock has a 50-day moving average price of $486.59 and a two-hundred day moving average price of $430.69. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $519.99.

Insider Buying and Selling

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $470.43, for a total transaction of $10,584,675.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 517,214 shares of company stock valued at $249,206,113 in the last 90 days. Company insiders own 10.30% of the company’s stock.

Wall Street Analyst Weigh In

UTHR has been the subject of a number of research reports. Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a research report on Wednesday, October 29th. Royal Bank Of Canada increased their price objective on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Wells Fargo & Company boosted their target price on shares of United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. UBS Group raised their price target on shares of United Therapeutics from $600.00 to $645.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $509.50.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.